444649-52-9

Basic information

• Product Name: Ethenamine, N,N-dimethyl-2-(2-methyl-4-pyridinyl)- (9CI)
• Synonyms: Ethenamine, N,N-dimethyl-2-(2-methyl-4-pyridinyl)- (9CI)
• CAS NO: 444649-52-9
• Molecular Formula: C10H14N2
• Molecular Weight: 162.23156
• Product Categories: AMINETERTIARY
• Mol File: 444649-52-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethenamine, N,N-dimethyl-2-(2-methyl-4-pyridinyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethenamine, N,N-dimethyl-2-(2-methyl-4-pyridinyl)- (9CI)(444649-52-9)
• EPA Substance Registry System: Ethenamine, N,N-dimethyl-2-(2-methyl-4-pyridinyl)- (9CI)(444649-52-9)

Safety Data

• Hazardous Substances Data: 444649-52-9(Hazardous Substances Data)

Upstream product

• 2417-93-8 propyllithium 
• 68-12-2 N,N-dimethyl-formamide 
• 108-47-4 2,4-lutidine 
• 109-89-7 diethylamine 

Downstream Products

• 63875-01-4 2-methyl-pyridine-4-carbaldehyde 

Relevant articles and documents

Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure

A novel class of therapeutic drug candidates for heart failure, highly potent and selective GRK2 inhibitors, exhibit potentiation of β-adrenergic signaling in vitro studies. Hydrazone derivative 5 and 1,2,4-triazole derivative 24a were identified as hit compounds by HTS. New scaffold generation and SAR studies of all parts resulted in a 4-methyl-1,2,4-triazole derivative with an N-benzylcarboxamide moiety with highly potent activity toward GRK2 and selectivity over other kinases. In terms of subtype selectivity, these compounds showed enough selectivity against GRK1, 5, 6, and 7 with almost equipotent inhibition to GRK3. Our medicinal chemistry efforts led to the discovery of 115h (GRK2 IC50 = 18 nM), which was obtained the cocrystal structure with human GRK2 and an inhibitor of GRK2 that potentiates β-adrenergic receptor (βAR)-mediated cAMP accumulation and prevents internalization of βARs in β2AR-expressing HEK293 cells treated with isoproterenol. Therefore, 115h appears to be a novel class of therapeutic for heart failure treatment.

IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.